Parkinson’s disease is most common among older people, with the majority of sufferers age 50 and above. Along with other neurodegenerative disorders, such as Huntington’s disease, it provides promising therapeutic targets for cannabinoid medicines, especially since the treatment options for these serious conditions are somewhat limited. Parkinson’s disease (PD) is a progressive neurodegenerative disease caused by the loss of neurons that produce the neurotransmitter dopamine within a small region in the midbrain called the substantia nigra. Reduced levels of dopamine interfere with coordination and motor function. The precise reason that these dopamine-producing neurons are lost in PD is still unknown although inflammation, along with environmental and hereditary factors, are thought to be partially responsible.134
PARKINSON’S DISEASE
Description
Stay updated, free articles. Join our Telegram channel
![](https://clinicalpub.com/wp-content/uploads/2023/09/256.png)
Full access? Get Clinical Tree
![](https://videdental.com/wp-content/uploads/2023/09/appstore.png)
![](https://videdental.com/wp-content/uploads/2023/09/google-play.png)